Researchers at the University of Duisburg‑Essen developed an automated stirred‑tank bioreactor process to generate large quantities of iPSC‑derived lung organoids, producing complex three‑dimensional lung structures at scale. The team demonstrated organoids that better recapitulate in vivo cellular diversity and proposed the system for high‑throughput drug testing and personalized disease modeling. Lead authors published methods and functional characterization in Frontiers in Bioengineering and Biotechnology and stressed the system’s potential to accelerate preclinical testing while reducing animal use. The development could fast‑track candidate screening for pulmonary diseases and support patient‑derived organoid applications.